Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy.

A Atanasio A Vanni L Maggi S Pilerci A Mazzoni M Capone F Crupi P Cicogna V Boldrini S Tekle M G Colao M Borella C Paoli G M Rossolini A M Vannucchi F Annunziato P Guglielmelli

Leuk Res

CRIMM, Centre of Research and Innovation in Myeloproliferative Neoplasms, University of Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Italy.

Published: August 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226289	PMC
http://dx.doi.org/10.1016/j.leukres.2023.107330	DOI Listing

Publication Analysis

Top Keywords

humoral cellular

cellular responses

responses third

third dose

dose sars-cov-2

sars-cov-2 vaccine

vaccine myeloproliferative

myeloproliferative neoplasms

neoplasms patients

patients ruxolitinib

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!